Evidence map›Paper›PMID 32303913›Full record

ArticleAdvances in therapy2020

Management of Retinitis Pigmentosa via Platelet-Rich Plasma or Combination with Electromagnetic Stimulation: Retrospective Analysis of 1-Year Results.

Umut Arslan, Emin Özmert

3 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04252534 nacompletednot on this map

Management of Retinitis Pigmentosa Via Repetitive Electromagnetic Stimulation and Autologous Platelet Rich Plasma

TypeinterventionalSponsorAnkara Universitesi TeknokentRan2017 to 2019Enrolled60ConditionsRetinitis PigmentosaArmsPRP combined Magnovision, PRP
NCT04877067 phase3completednot on this map

Bioretina Inc Ankara University Technopolis

TypeinterventionalSponsorAnkara Universitesi TeknokentRan2019 to 2021Enrolled18ConditionsMethanol Poisoning, Toxic Optic Neuropathy, Stem Cell Tyrosine Kinase 1 Y842X, Magnetic Field ExposureArmsWharton jelly derived mesenchymal stem cell, Repetitive electromagnetic stimulation
NCT05800301 phase3completednot on this map

Bioretina, Ankara University Technopolis

TypeinterventionalSponsorAnkara Universitesi TeknokentRan2019 to 2022Enrolled80ConditionsRetinitis PigmentosaArmsWharton's jelly derived mesenchymal stemcells, Magnovision
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Umut ArslanAnkara University Technopolis, Ankara, Turkey. drumutarslan@hotmail.com.
Emin ÖzmertDepartment of Ophthalmology, Faculty of Medicine, Ankara University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate whether the natural progression rate of retinitis pigmentosa can be decreased by subtenon autologous platelet-rich plasma application alone or combination with retinal electromagnetic stimulation.

methodsThe study includes retrospective analysis of 60 patients with retinitis pigmentosa. Patients constitute three groups with similar demographic characteristics: the combined management group (group 1) consists of 20 patients with retinitis pigmentosa (40 eyes) who received combined retinal electromagnetic stimulation and subtenon platelet-rich plasma; the subtenon platelet-rich plasma-only group (group 2) consisted of 20 patients with retinitis pigmentosa (40 eyes); the natural course (control) group (group 3) consists of 20 patients with retinitis pigmentosa (40 eyes) who did not receive any treatment. Horizontal and vertical ellipsoid zone width, fundus perimetry deviation index, and best corrected visual acuity changes were compared within and between groups after a 1-year follow-up period.

resultsDetected horizontal ellipsoid zone percentage changes were + 1% in group 1, - 2.85% in group 2, and - 9.36% in group 3 (Δp 1 > 2 > 3). Detected vertical ellipsoid zone percentage changes were + 0.34% in group 1, - 3.05% in group 2, and - 9.09% in group 3 (Δp 1 > 2 > 3). Detected fundus perimetry deviation index percentage changes were + 0.05% in group 1, - 2.68% in group 2, and - 8.78% in group 3 (Δp 1 > 2 > 3).

conclusionPlatelet-rich plasma is a good source of growth factors, but its half-life is 4-6 months. Subtenon autologous platelet-rich plasma might more effectively slow down photoreceptor loss when repeated as booster injections and combined with retinal electromagnetic stimulation.

trial registrationClinicalTrials.gov identifier, NCT04252534.

Indexed as

Platelet-Rich PlasmaAdultCombined Modality TherapyDisease ProgressionFemaleHumansMagnetic Field TherapyMaleMiddle AgedRetinitis PigmentosaRetrospective StudiesVisual AcuityVisual Field TestsElectromagnetic stimulationGrowth factorsIontophoresisMagnovisionOphthalmologyPlatelet-rich plasmaRetinitis pigmentosa

Identifiers

PMID32303913

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.